Genetic screening, testing and treatment: How far can we go?

Journal of Inherited Metabolic Disease

Volumn 19, Issue 4, 1996, Pages 401-411

  Scriver, C R ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; GENETIC DISORDER; GENETIC SCREENING; HEALTH CARE; HOMEOSTASIS; HUMAN;

EID: 0029785461     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01799101     Document Type: Conference Paper

References (33)

1. Bodmer W (1995) Where will genome analysis lead us 40 years on? Ann NY Acad Sci 758: 414-426.
2. Cavalli-Sforza LL, Menozzi P, Piazza A (1994) The History and Geography of Human Genes. Princeton, NJ: Princeton University Press.
3. Chambers DA, Reid KBM, Cohen RL (1995) The biochemical revolution at 40 years. Ann NY Acad Sci 758: 441-458.
4. Childs B (1995) A logic of disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 229-257.
5. Childs B, Scriver CR (1986) Age at onset and cause of disease. Perspect Biol Med 29: 437-460.
6. Cotton RGH (1993) Current methods of mutation detection. Mutat Res 285: 125-144.
7. Cystic Fibrosis Genetic Analysis Consortium (1994) Population variation of common cystic fibrosis mutations. Hum Mutat 4: 167-177.
8. Forfar JO (1990) Pediatrics in a changing world. J.H. Hutchison Memorial Lecture. Hong Kong J Paediatr 7: 133-148.
9. Forrest S, Cotton R, Landegren U, Southern E (1995) How to find all those mutations. Nature Genetics 10: 375-376.
10. Garrod AE (1931) The Inborn Factors in Disease. An Essay. Oxford: Clarendon Press.
11. Goldstein JL, Hobbs HH, Brown MS (1995) Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly S, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1981-2030.
12. Gori GB, Richter BJ (1978) Macroeconomics of disease. Prevention in the United States. Science 200: 1124-1130.
13. Grompe M (1993) The rapid detection of unknown mutations in nucleic acids. Nature Genetics 5: 111-117.
14. Hayes A, Costa T, Scriver CR, Childs B (1985) The effect of Mendelian disease on human health: II. Response to treatment. Am. J Med Genet B21: 243-255.
15. Institute of Medicine (1994) Assessing Genetic Risks. Implications for Health and Social Policy. Washington, DC: National Academy Press.
16. Knoppers BM, Chadwick R (1994) The human genome project: under an international ethical microscope. Science 265: 2035-2036.
17. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340: 813-817.
18. National Academy of Sciences (1975) Genetic Screening. Programs, Principles, and Research. Washington, DC: National Academy Press.
19. Nowak R (1994) Genetic testing set for take off: news and comment. Science 265: 464-467.
20. PAH Mutation Analysis Consortium (1995). Scriver CR, Hoang L, Byck S, Prevost L, curators. Database, Newsletter and World Wide Web server, http://www.mcgill.ca/pahdb July 1995. PAH Mutation Analysis Consortium.
21. Science Council of Canada (1991) Genetics in Canadian Health Care. Report #42. Ministry of Supply and Services.
22. Scriver CR (1976) Realized and potential neutralization of mutant genes in man by nutritional selection. Fed Proc 35: 2286-2290.
23. Scriver CR (1982) Treatment of inborn errors of metabolism. The nature:nurture argument specified. In: Crawfurd MD, Gibbs DA, Watts RWE, eds. Advances in the Treatment of Inborn Errors of Metabolism. New York: Wiley, 289-303.
24. Scriver CR (1983) Genetic screening: implications for preventive medicine. Am J Publ Health 73: 243-245.
25. Scriver CR (1984) The Canadian Rutherford Lecture. An evolutionary view of disease in man. Proc R Soc (London) 220: 273-298.
26. Scriver CR (1988) We mean well: Treatment of Mendelian disease. Acta Paediatr Japonica 30: 385-389.
27. Scriver CR (1993) Every disease has two histories. Trans R Soc Can, Sixth Series. IV 19-32.
28. Scriver CR (1995) Book review: Assessing genetic risks. Am J Hum Genet 56: 814-816.
29. Scriver CR, Childs B (1989) Garrod's Inborn Factors in Disease. Oxford: Oxford University Press, xii-248.
30. Scriver CR, Brock DJH, Cuckle HS, et al (1985) Population screening: report of a workshop. Prog Clin Biol Res 168B: 89-152.
31. Sorensen TIA, Nielsen GG, Anderson P-K, Teasdale TW (1988) Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 318: 727-732.
32. Treacy E, Childs B, Scriver CR (1995) Response to treatment in hereditary metabolic disease: 1993 survey and 10-year comparison. Am J Hum Genet 56: 356-367.
33. US Congress Office of Technology Assessment (1992) Cystic fibrosis and DNA tests: implications of carrier screening. OTA-BA-532.